// App-Quantinova.ai

: Liraglutide reduces cardiovascular events and mortality in type 2 diabetes independent of LDL cholesterol and statin use: results of the LEADER trial

Researchers

Presenter

  • S Verma

Principal Investigators

  • L A Leiter

  • C D Mazer

  • S C Bain

  • J Buse

  • S Marso

  • M Nauck

  • B Zinman

  • H Bosch-Traberg

  • H Frimer-Larsen

Medical Centers

  • St Michaels Hospital, Respiratory Medicine, Toronto, Canada

  • ABMU / Swansea University, Swansea, United Kingdom.

  • University of North Carolina Hospitals, Chapel Hill, United States of America

  • HCA Midwest Health Heart & Vascular Institute, Kansas City, United States of America

  • Ruhr-University Bochum, Bochum, Germany

  • Novo NordiskA/S, Soborg, Denmark

Locations

  • Canada

  • United Kingdom

  • Germany

  • Denmark

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Liraglutide

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved